18 October 2018 
EMA/CHMP/701490/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
NovoSeven 
eptacog alfa (activated) 
On 18 October 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
NovoSeven. The marketing authorisation holder for this medicinal product is Novo Nordisk A/S. 
The CHMP adopted an extension to an existing indication as follows:2  
“NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those 
undergoing surgery or invasive procedures in the following patient groups: 
• 
• 
• 
• 
• 
in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5  Bethesda 
Units (BU) 
in patients with congenital haemophilia who are expected to have a high anamnestic response to factor 
VIII or factor IX administration 
in patients with acquired haemophilia 
in patients with congenital FVII deficiency 
in patients with Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA, and past or 
present refractoriness to platelet transfusions, or where platelets are not readily available.” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
                                                
